Oral weight-loss formulations cannot replicate the commercial momentum of their injectable predecessors.
Underperforming sales and severe gastrointestinal side effects are stalling the market adoption of early oral obesity medications compared to high-growth injectable franchises.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
The flagship oral therapies plateaued at a small fraction of injectable volumes and pulled back class-wide, stalling the oral ramp the market had priced in.
High gastrointestinal adverse events like nausea and vomiting continue to hamper the commercial potential and patient tolerability of oral GLP-1 candidates.
Even with massive marketing muscle, Eli Lilly's new oral pill missed initial commercial targets while its flagship injectables continued to blow out revenue forecasts.
Novo Nordisk's oral Wegovy tablet missed sales expectations even as the company navigated significant clinical and competitive pressures.